Sali-NP-HER2 nanoparticles efficiently bound to HER2-positive BCSCs and BC cells, resulting in enhanced cytotoxic effects compared with non-targeted nanoparticles or salinomycin. This evidence concerns the gene ERBB2 and breast cancer.